Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Basel, January 5, 2024— Novartis announced today that it has received approval from the US Food and Drug Administration for commercial manufacturing of Pluvicto TM at its new large-scale, state ...

Novartis is committed to improving access to its RLTs, Pluvicto and Lutathera ® (INN: lutetium (177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) by adding more treatment sites in closer ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

For Novartis, investing in the infrastructure to produce and distribute radiopharmaceuticals would be worthwhile for Pluvicto and Lutathera alone, Bulto said. But it's even more attractive because ...

Novartis received approval from the Food and Drug Administration to produce its Pluvicto radioligand therapy at its new manufacturing facility in Indianapolis, expanding capacity to meet growing ...

Novartis shares fell 4% in Zurich, trimming this year’s gain to 12%, after sales of the treatment fell short of analysts’ estimates. “Pluvicto’s a little bit behind, but we believe that in ...

Novartis reports strong Q2 2024 sales, with Kesimpta and Pluvicto showing significant growth. Learn more about NVSEF stock and their expanding product portfolio. Skip to content ...

Novartis is expanding U.S. production of cancer drug Pluvicto, a build-up that will help the therapy see blockbuster sales. The Swiss drugmaker said Friday it won Food and Drug Administration ...

Thursday, Novartis AG NVS shares are trading higher after the company confirmed plans to file for Pluvicto pre-taxane label expansion in the second half of 2024 based on data from its Phase 3 ...